CoChat

Anamorelin in Japanese patients with cancer cachexia: an update

Wakabayashi, Hidetaka, Arai, Hidenori, Inui, Akio · 2023 · Current Opinion in Supportive & Palliative Care

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

Purpose of review: Anamorelin was approved for production and marketing in Japan on 22 January 2021 for cancer cachexia in non-small-cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer. The authors describe the updates of anamorelin for cancer cachexia in Japan. Recent findings: Recent evidence showed that anamorelin improved lean body mass, body weight, and appetite in patients with cancer cachexia in clinical practice. Anamorelin does not increase body weight in the severe-weight-loss group in cachectic patients with pancreatic cancer. Several case reports showed that anamorelin can cause cardiac adverse drug reactions. Among the cardiac adverse reactions, fatal arrhythmias should be monitored carefully even if it is the first dose. Anamorelin combined with nutrition, physical activity, and exercise may be more useful than anamorelin alone for treating cancer cachexia. An interim analysis from post-marketing all-case surveillance was performed; however, details have not yet been published. When anamorelin cannot be used for cancer cachexia, Kampo medicines can be considered as an option. Summary: Anamorelin has changed the clinical practice of cancer cachexia in Japan. The authors hope that anamorelin is available for other disease-related cachexia along with appropriate multidisciplinary interventions.

Overview

Integrity signals

Registry

Crossref · 10.1097/spc.0000000000000658

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 29 references

Research works printed but not linked: 2

  1. Takayama, Real-world safety and effectiveness of anamorelin in patients with cancer cachexia in Japan: an interim analysis from post-marketing all-case surveillance (O077-1), The Japan Society of Clinical Oncology
  2. Takayama, Real-world outcomes of anamorelin in patients with non-small cell lung cancer in Japan (O58-1), The Japan Lung Cancer Society Online Journal

Cited by

See all 18

Metadata

Authors
Wakabayashi, H., Arai, H., & Inui, A.
Affiliations
  • Tokyo Women's Medical University Hospital (JP)
  • National Center for Geriatrics and Gerontology (JP)
  • Kagoshima University (JP)
Corresponding author
Wakabayashi, Hidetaka
Venue
Current Opinion in Supportive & Palliative Care
Published
2023-06-30
Volume
17
Issue
3
Pages
162-167
ISSN
1751-4258 (ISSN-L)
OpenAlex
W4382630874
Cited by
17
References
28
Citations by year
2026: 2 · 2025: 6 · 2024: 8 · 2023: 1
FWCI
0.61
Type
journal article
Language
en
Open access
closed
Locations
  • Current Opinion in Supportive and Palliative Care (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
  • Health Sciences › Nursing › Nutrition and Dietetics › Clinical Nutrition and Gastroenterology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
Keywords
anamorelin, cancer cachexia, Japanese patients, non-small cell lung cancer, gastric cancer, pancreatic cancer, colorectal cancer, lean body mass, body weight, appetite, cardiac arrhythmias, Kampo medicine, multidisciplinary intervention, post-marketing surveillance
MeSH terms
East Asian People, Body Weight, Cachexia, Carcinoma, Non-Small-Cell Lung, Humans, Hydrazines, Lung Neoplasms, Neoplasms, Oligopeptides, Pancreatic Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anamorelin in Japanese patients with cancer cachexia: an update. https://app.cochat.ai/papers/10.1097/spc.0000000000000658
The paper
Wakabayashi, H., Arai, H., & Inui, A. (2023). Anamorelin in Japanese patients with cancer cachexia: an update. Current Opinion in Supportive & Palliative Care. https://doi.org/10.1097/spc.0000000000000658

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.